Sunshine Guojian Pharmaceutical Shanghai Co Ltd

Sansheng Guojian released its 2026 semi-annual report, achieving attributable net profit of about 371 million yuan in the first half, up 95.1% year on year. During the reporting period, the company achieved operating revenue of about 866 million yuan, up 34.84% year on year. The company is mainly engaged in the research and development, production and sales of antibody drugs, and currently has 22 innovative autoimmune drug candidates in different stages of development. Sansheng Guojian said that with the successful approval and launch of Yisaituo in February 2026, the company has officially entered a new round of product harvest cycle.

Sansheng Guojian released its semi-annual report for 2026, achieving operating revenue of 866 million yuan, up 34.84% year on year. Net profit attributable to shareholders of the listed company was 371 million yuan, up 95.1% year on year. The company plans to distribute a cash dividend of 0.42 yuan per 10 shares, tax included, to all shareholders. Net profit for the second quarter was 193 million yuan, while net profit for the first quarter was 178 million yuan, meaning second-quarter net profit rose 8% quarter on quarter.

Sansheng Guojian's self-developed Class 1 innovative biologic drug, aflibercept monoclonal antibody injection, has been approved for market. The drug is a subcutaneous injection indicated for the treatment of acute gouty arthritis attacks in adults for whom nonsteroidal anti-inflammatory drugs and/or colchicine are contraindicated, intolerable, or ineffective, and who are unsuitable for repeated corticosteroid use. A single dose provides rapid pain relief, reduces the risk of acute attacks by 77% within 12 weeks, and demonstrates good overall safety and tolerability.